A randomized, placebo‐controlled clinical development program exploring the use of litoxetine for treating urinary incontinence. Issue 6 (29th June 2021)

• Record Type: Journal Article
• Authors: Dmochowski, Roger R.; Haab, Francois; Robinson, Dudley
• Is Part Of: Neurourology and urodynamics. Volume 40:Issue 6(2021)
• Page Start: 1515
• Page End: 1523
• Publication Date: 2021-06-29
• Subjects: litoxetine -- mixed urinary incontinence -- randomized controlled trial -- urinary incontinence; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.24690
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract: Aims: To investigate the safety and efficacy of litoxetine, a serotonin reuptake inhibitor, in treating urinary incontinence (UI) and mixed urinary incontinence (MUI). Methods: Two randomized, double‐blind, placebo‐controlled clinical trials (RCT1 and RCT2) were conducted. RCT1, which included 196 women aged 18–75 with MUI randomized 1:1:1:1 to receive 10, 20, or 40 mg litoxetine or placebo orally twice daily (BID) for 12 weeks, investigated the efficacy (including changes in patient reported outcomes) and safety of litoxetine compared to placebo. RCT2, which included 82 men and women aged 18–70 with any UI type randomly assigned 2:1 to receive 30 mg litoxetine or placebo orally BID for 8 weeks including a 2 week dose titration period, investigated the safety (including psychiatric safety) and efficacy of litoxetine compared to placebo. Efficacy was measured as the change in number of incontinence episodes per week and assessed using an analysis of covariance with missing data imputed by Predictive Mean Matching. Safety was assessed by adverse events (AEs) and physical examinations and analyzed using descriptive statistics. Results: The 30‐mg and placebo groups in RCT2 showed no difference in frequency of AEs, and litoxetine reduced the number of incontinence episodes per week compared to placebo. Although RCT1 suffered an unexpectedly high placebo response, and therefore did not meet the primary efficacy endpoint, 71% of participants receiving 40 mg litoxetine reported a clinically meaningful improvement in the King's Health Questionnaire. Conclusions: Litoxetine may be a safe, effective and well‐tolerated treatment for patients with UI.